Search

Your search keyword '"Honarpour, Narimon"' showing total 199 results

Search Constraints

Start Over You searched for: Author "Honarpour, Narimon" Remove constraint Author: "Honarpour, Narimon"
199 results on '"Honarpour, Narimon"'

Search Results

1. A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings

2. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.

4. Evaluation of Large-Scale Proteomics for Prediction of Cardiovascular Events

5. Heart Failure With Preserved Ejection Fraction Expert Panel Report: Current Controversies and Implications for Clinical Trials

6. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial

7. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study

10. List of Contributors

12. Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial

13. Evaluation of Large-Scale Proteomics for Prediction of Cardiovascular Events

19. Abstract 15100: Reduction in Total Cardiovascular Events With the PCSK9 Inhibitor Evolocumab in Patients With Cardiovascular Disease in the FOURIER Trial

21. Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency

23. The effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure ( COSMIC ‐ HF )

24. The effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure (COSMIC-HF)

25. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure

26. Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy

28. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure

29. Loss of Apaf-1 leads to partial rescue of the HAND2-null phenotype

31. The Effect of the Cardiac Myosin Activator, Omecamtiv Mecarbil, on Right Ventricular Structure and Function in Chronic Systolic Heart Failure (cosmic-hf)

33. Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction

34. Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction

35. THE EFFECT OF THE CARDIAC MYOSIN ACTIVATOR, MECAMTIV MECARBIL, ON RIGHT VENTRICULAR STRUCTURE AND FUNCTION IN CHRONIC SYSTOLIC HEART FAILURE (COSMIC-HF)

36. Adult Apaf-1-Deficient Mice Exhibit Male Infertility

38. Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease

40. EFFECT OF OMECAMTIV MECARBIL IN PATIENTS WITH ATRIAL FIBRILLATION AND HEART FAILURE WITH REDUCED EJECTION FRACTION: RESULTS FROM COSMIC-HF

41. Evolocumab and clinical outcomes in patients with cardiovascular disease

42. Association between systolic ejection time and outcomes in heart failure by ejection fraction.

43. RESIDUAL INFLAMMATORY AND CHOLESTEROL RISK IN THE FOURIER TRIAL

44. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial

45. Erratum to 'Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency' [Eur J Heart Fail 2016;18:482-489]

46. Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency

47. Cognitive Function in a Randomized Trial of Evolocumab

49. New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment

Catalog

Books, media, physical & digital resources